128 related articles for article (PubMed ID: 16553547)
1. Development of a live attenuated dengue virus vaccine using reverse genetics.
Blaney JE; Durbin AP; Murphy BR; Whitehead SS
Viral Immunol; 2006; 19(1):10-32. PubMed ID: 16553547
[TBL] [Abstract][Full Text] [Related]
2. The dengue virus 4 component of NIAID's tetravalent TV003 vaccine drives its innate immune signature.
Pintado Silva J; Fenutria R; Bernal-Rubio D; Sanchez-Martin I; Hunziker A; Chebishev E; Veloz J; Kelly G; Kim-Schulze S; Whitehead S; Durbin A; Ramos I; Fernandez-Sesma A
Exp Biol Med (Maywood); 2022 Dec; 247(24):2201-2212. PubMed ID: 36734144
[TBL] [Abstract][Full Text] [Related]
3. Development of DENVax: a chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever.
Osorio JE; Huang CY; Kinney RM; Stinchcomb DT
Vaccine; 2011 Sep; 29(42):7251-60. PubMed ID: 21777638
[TBL] [Abstract][Full Text] [Related]
4. Dengue type 4 live-attenuated vaccine viruses passaged in vero cells affect genetic stability and dengue-induced hemorrhaging in mice.
Lee HC; Yen YT; Chen WY; Wu-Hsieh BA; Wu SC
PLoS One; 2011; 6(10):e25800. PubMed ID: 22053180
[TBL] [Abstract][Full Text] [Related]
5. Targeted mutagenesis as a rational approach to dengue virus vaccine development.
Blaney JE; Durbin AP; Murphy BR; Whitehead SS
Curr Top Microbiol Immunol; 2010; 338():145-58. PubMed ID: 19802584
[TBL] [Abstract][Full Text] [Related]
6. Latest developments and future directions in dengue vaccines.
Thisyakorn U; Thisyakorn C
Ther Adv Vaccines; 2014 Jan; 2(1):3-9. PubMed ID: 24757522
[TBL] [Abstract][Full Text] [Related]
7. Dengue Vaccine: The Current Status.
Mustafa MS; Agrawal VK
Med J Armed Forces India; 2008 Apr; 64(2):161-4. PubMed ID: 27408122
[TBL] [Abstract][Full Text] [Related]
8. Updates in the Management of Dengue Shock Syndrome: A Comprehensive Review.
Singh RK; Tiwari A; Satone PD; Priya T; Meshram RJ
Cureus; 2023 Oct; 15(10):e46713. PubMed ID: 38021722
[TBL] [Abstract][Full Text] [Related]
9. The Difference of sVE-Cadherin Levels between Dengue Hemorrhagic Fever Patients with Shock and without Shock.
Mariko R; Darwin E; Yanwirasti Y; Hadinegoro SR
Open Access Maced J Med Sci; 2019 Jul; 7(14):2277-2281. PubMed ID: 31592274
[TBL] [Abstract][Full Text] [Related]
10. Reverse genetics approaches for the development of mammarenavirus live-attenuated vaccines.
Ye C; de la Torre JC; Martinez-Sobrido L
Curr Opin Virol; 2020 Oct; 44():66-72. PubMed ID: 32721864
[TBL] [Abstract][Full Text] [Related]
11. Immunization against dengue virus infection is coercive: A timely call.
Ahmed I; Ahamed R; Nahar S; Bari LF; Dewan SMR
Health Sci Rep; 2024 Jun; 7(6):e2170. PubMed ID: 38845788
[TBL] [Abstract][Full Text] [Related]
12. Dengue viral infections.
Gurugama P; Garg P; Perera J; Wijewickrama A; Seneviratne SL
Indian J Dermatol; 2010; 55(1):68-78. PubMed ID: 20418983
[TBL] [Abstract][Full Text] [Related]
13. Dengue: challenges for policy makers and vaccine developers.
Wilder-Smith A; Macary P
Curr Infect Dis Rep; 2014 May; 16(5):404. PubMed ID: 24781826
[TBL] [Abstract][Full Text] [Related]
14. Human antibody response to dengue virus: implications for dengue vaccine design.
Moi ML; Takasaki T; Kurane I
Trop Med Health; 2016; 44():1. PubMed ID: 27398060
[TBL] [Abstract][Full Text] [Related]
15. Identification and quantitation of multiple variants in RNA virus genomes.
Sena J; Karwal L; Bell C; Devitt N; Schilkey F; Huang C; Livengood J; Das S; Dean HJ
Biol Methods Protoc; 2024; 9(1):bpae004. PubMed ID: 38414646
[TBL] [Abstract][Full Text] [Related]
16. Robust and Balanced Immune Responses to All 4 Dengue Virus Serotypes Following Administration of a Single Dose of a Live Attenuated Tetravalent Dengue Vaccine to Healthy, Flavivirus-Naive Adults.
Kirkpatrick BD; Durbin AP; Pierce KK; Carmolli MP; Tibery CM; Grier PL; Hynes N; Diehl SA; Elwood D; Jarvis AP; Sabundayo BP; Lyon CE; Larsson CJ; Jo M; Lovchik JM; Luke CJ; Walsh MC; Fraser EA; Subbarao K; Whitehead SS
J Infect Dis; 2015 Sep; 212(5):702-10. PubMed ID: 25801652
[TBL] [Abstract][Full Text] [Related]
17. A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trial.
Durbin AP; Kirkpatrick BD; Pierce KK; Elwood D; Larsson CJ; Lindow JC; Tibery C; Sabundayo BP; Shaffer D; Talaat KR; Hynes NA; Wanionek K; Carmolli MP; Luke CJ; Murphy BR; Subbarao K; Whitehead SS
J Infect Dis; 2013 Mar; 207(6):957-65. PubMed ID: 23329850
[TBL] [Abstract][Full Text] [Related]
18. The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model.
Kirkpatrick BD; Whitehead SS; Pierce KK; Tibery CM; Grier PL; Hynes NA; Larsson CJ; Sabundayo BP; Talaat KR; Janiak A; Carmolli MP; Luke CJ; Diehl SA; Durbin AP
Sci Transl Med; 2016 Mar; 8(330):330ra36. PubMed ID: 27089205
[TBL] [Abstract][Full Text] [Related]
19. Dengue vaccine candidates in development.
Durbin AP; Whitehead SS
Curr Top Microbiol Immunol; 2010; 338():129-43. PubMed ID: 19802583
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
